Relapse-free and overall survival in patients with pathologic stage II nonseminomatous germ cell cancer treated with etoposide and cisplatin adjuvant chemotherapy

Journal of Clinical Oncology

Volumn 22, Issue 3, 2004, Pages 464-467

  Kondagunta, G Varuni ^a   Sheinfeld, Joel ^a   Mazumdar, Madhu ^a   Mariani, Tania V ^a   Bajorin, Dean ^a   Bacik, Jennifer ^a   Bosl, George J ^a   Motzer, Robert J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CISPLATIN; ETOPOSIDE; ANTINEOPLASTIC AGENT; VP P PROTOCOL; VP-P PROTOCOL;

ADJUVANT CHEMOTHERAPY; ARTICLE; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; NON SEMINOMATOUS GERMINOMA; PRIORITY JOURNAL; ADOLESCENT; ADULT; CLINICAL TRIAL; DISEASE FREE SURVIVAL; GERM CELL TUMOR; LYMPH NODE; LYMPHADENECTOMY; MIDDLE AGED; MORTALITY; PATHOLOGY; PHASE 2 CLINICAL TRIAL; RETROPERITONEUM; RETROSPECTIVE STUDY; SURVIVAL RATE; TESTIS TUMOR; TUMOR RECURRENCE;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DISEASE-FREE SURVIVAL; ETOPOSIDE; FOLLOW-UP STUDIES; GERMINOMA; HUMANS; LYMPH NODE EXCISION; LYMPH NODES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RETROPERITONEAL SPACE; RETROSPECTIVE STUDIES; SURVIVAL RATE; TESTICULAR NEOPLASMS;

EID: 1442265954     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.07.178     Document Type: Article

References (15)

1. Bosl GJ, Motzer RJ: Testicular germ-cell cancer. N Engl J Med 337:242-253, 1997
2. Motzer RJ, Sheinfeld J, Mazumdar M, et al: Etoposide and cisplatin adjuvant therapy for patients with pathologic stage II germ cell tumors. J Clin Oncol 13:2700-2704, 1995
3. Vugrin D, Whitmore WF, Cvitkovic E, et al: Adjuvant chemotherapy combination of vinblastine, actinomycin D, bleomycin, and chlorambucil following retroperitoneal lymph node dissection for stage II testis tumor. Cancer 47:840-844, 1981
4. Vugrin D, Whitmore W, Cvitkovic E, et al: Adjuvant chemotherapy with VAB-3 of stage II-B testicular cancer. Cancer 48:233-237, 1981
5. Vugrin D, Whitmore WF Jr, Herr H, et al: Adjuvant vinblastine, actinomycin D, bleomycin, cyclophosphamide and cis-platinum chemotherapy regimen with and without maintenance in patients with resected stage IIB testis cancer. J Urol 128:715-717, 1982
6. Hartlapp JH, Weissbach L, Bussar-Maatz R: Adjuvant chemotherapy in nonseminomatous testicular tumour stage II. Int J Androl 10:277-284, 1987
7. Pizzocaro G, Monfardini S: No adjuvant chemotherapy in selected patients with pathologic stage II nonseminomatous germ cell tumors of the testis. J Urol 131:677-680, 1984
8. Fraley EE, Narayan P, Vogelzang NJ, et al: Surgical treatment of patients with stages I and II nonseminomatous testicular cancer. J Urol 134:70-73, 1985
9. Williams SD, Birch R, Einhorn LH, et al: Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 316:1435-1440, 1987
10. Walsh P, Retik AB, Vaughan ED, et al (eds): Surgery of testicular tumors, in Cambell's Urology (ed 8). Philadelphia, PA, Elsevier Scientific Publications, 2002, pp 2920-2930
11. Kaplan FL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 52:457-481, 1958
12. Motzer RJ, Sheinfeld J, Mazumdar M, et al: Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer. J Clin Oncol 18:2413-2418, 2000
13. DeVita VJ, Hellman S, Rosenberg SA (eds): Chapter 35, in Cancer: Principles and Practice (ed 6). Philadelphia, PA, Lippincott Williams & Wilkins, 2001, pp 1491-1518
14. Xiao H, Mazumdar M, Bajorin DF, et al: Long-term follow-up of patients with good-risk germ cell tumors treated with etoposide and cisplatin. J Clin Oncol 15:2553-2558, 1997
15. Behnia M, Foster R, Einhorn LH, et al: Adjuvant bleomycin, etoposide and cisplatin in pathological stage II non-seminomatous testicular cancer: The Indiana University experience. Eur J Cancer 36:472-475, 2000